Low-Dose Atropine for Children’s Myopia Control

Low-dose atropine refers to highly diluted atropine eye drops, typically at concentrations between 0.01% and 0.05%, used nightly to slow the progression of myopia (nearsightedness) in children. In a three-year randomized trial, 0.01% atropine significantly slowed both the worsening of the prescription and the physical elongation of the eye compared with placebo. The treatment has become one of the most studied interventions in pediatric myopia management, though the ideal concentration, treatment duration, and what happens after stopping remain active questions with answers that depend on the child’s age, ethnicity, and rate of progression.

Why Children’s Myopia Progression Matters

Myopia usually develops during childhood and tends to worsen year by year until the late teens or early twenties, as the eyeball grows slightly too long from front to back. Each additional unit of nearsightedness isn’t just a thicker lens in the glasses. Higher myopia later in life raises the odds of serious complications like retinal detachment, glaucoma, and a form of degeneration at the back of the eye that can permanently impair vision. Slowing progression by even a moderate amount during childhood can meaningfully reduce those long-term risks. That is the rationale behind low-dose atropine: not to reverse myopia, but to put the brakes on how fast it gets worse while the eye is still growing.

How Effective Is It

The evidence for low-dose atropine has been building steadily since the early 2010s, with several large randomized trials now reporting multi-year results. In a three-year trial comparing 0.01% and 0.02% atropine against placebo, children receiving 0.01% atropine had their prescription worsen by about a quarter of a diopter less than the placebo group, and their eye elongation was slowed by roughly 0.13 millimeters. The proportion of children classified as “responders” was also about four and a half times higher with 0.01% atropine than with placebo.¹ Those numbers may sound small, but they accumulate over the years a child’s eye is still growing.

A five-year follow-up from the influential LAMP study provided longer-term data and showed a clear dose-response pattern. Children who started on 0.05% atropine and continued treatment progressed by about 1.3 diopters over five years, while those on 0.01% progressed by about 2.3 diopters, with 0.025% falling in the middle. The same pattern held for eye elongation.² In practical terms, higher concentrations worked better at slowing myopia, but the trade-off involves more side effects, which is why dosing remains a balancing act.

Choosing a Concentration

The three concentrations that have been most widely studied are 0.01%, 0.025%, and 0.05%. The 0.01% dose became popular first because early research suggested it offered a good balance: modest slowing of progression with almost no noticeable side effects. But as more data came in, particularly from the LAMP study, it became clear that 0.01% is the weakest performer of the three, and some researchers have shifted toward recommending 0.025% or 0.05% as initial therapy for children whose myopia is progressing quickly.

The concentration-dependent pattern holds across age groups. A study from the LAMP group found that at every year of age from 4 to 12, the higher-concentration drops produced a better treatment response.³ This doesn’t mean 0.01% is useless, but it does suggest that one-size-fits-all prescribing at the lowest dose may undertreat some children, especially those who are young or progressing rapidly.

Age and Rate of Progression

Age is one of the strongest predictors of how well a child responds to low-dose atropine. Younger children tend to have poorer responses regardless of concentration, because their eyes are growing faster. The same LAMP analysis found that for each younger year of age, the treatment effect diminished, and this held true at all three concentrations tested.⁴ That finding creates a clinical tension: the children who need myopia control the most, those who become myopic very early, are also the ones for whom a given dose works least effectively.

How fast a child’s prescription is worsening also matters. Research from an Indian population found that 0.01% atropine was more effective at halting axial eye growth in slow progressors compared with fast progressors. Children worsening at less than 0.75 diopters per year saw almost 80% of their axial elongation controlled, while fast progressors saw closer to 43%.⁵ A child whose myopia is galloping ahead may need a higher concentration, a combination strategy, or both.

Ethnicity and Treatment Response

Most of the landmark low-dose atropine trials were conducted in East Asian populations, where childhood myopia rates are extremely high. A recent systematic review and meta-analysis examined whether those results translate to other ethnic groups and found that atropine’s effectiveness appears greater in Asian children, particularly East Asians, who also show more pupil dilation in response to the drops.⁶ This doesn’t mean atropine is ineffective in non-Asian populations, but it does suggest that the dramatic effect sizes seen in some Asian-based studies may not fully replicate elsewhere. Eye doctors treating children from different backgrounds may need to adjust expectations and potentially combine treatments rather than relying on atropine alone.

How It Works

For something used so widely, the mechanism behind low-dose atropine is surprisingly unsettled. Atropine is a muscarinic receptor blocker, and the original assumption was that it worked by paralyzing the focusing muscle inside the eye, preventing the accommodation strain that was thought to drive myopia. But that theory doesn’t hold up well anymore. Animal studies have shown that myopia develops and the eye elongates even when the optic nerve is severed, meaning the signal driving eye growth doesn’t rely on the focusing pathway at all.⁷ So blocking accommodation isn’t the whole story, or perhaps even the main story.

The leading alternative theory involves the sclera, the white outer shell of the eye. In myopic eyes, the sclera remodels and thins as the eye elongates. Animal research has found that anti-muscarinic drugs like atropine can alter collagen structure and the production of proteins in the sclera during myopia development, essentially stiffening or slowing the remodeling process.⁸ Another clue comes from the choroid, the blood-vessel-rich layer between the retina and sclera. Low-dose atropine thickens the choroid, and a thicker choroid is generally associated with less myopic progression. One study in young myopic adults found a statistically significant increase in choroidal thickness of about 6 micrometers with a single dose of 0.01% atropine.⁹ A meta-analysis of studies in myopic children confirmed this choroidal thickening effect and found it was statistically significant after just one month of treatment.¹⁰

It’s likely that multiple mechanisms are at play, involving muscarinic receptors in the retina, choroid, and sclera simultaneously. The field hasn’t nailed down a single pathway, which is part of why dosing remains somewhat empirical rather than driven by a clean pharmacological model.

Side Effects at Low Doses

One of the main selling points of low-dose atropine over higher concentrations (1% or 0.5%, which ophthalmologists have long used for diagnostic purposes) is its much milder side-effect profile. Full-strength atropine dilates the pupil dramatically and paralyzes the eye’s focusing ability for days, causing severe light sensitivity and inability to read up close. Low-dose formulations still affect the pupil and accommodation, but far less.

In a study of young adults, 0.01% atropine had only minor effects on pupil size, with a small residual effect still detectable in the evening after morning application. At 0.005%, the pupil was back to nearly normal within 24 hours, and at 0.001%, there were no measurable effects on either pupil size or the ability to focus up close.¹¹ That study concluded that the effects of low-dose atropine were small enough to pose no barrier to long-term use.

In the three-year clinical trial mentioned earlier, the rates of treatment-emergent side effects were actually similar between the atropine groups and the placebo group. About 60% of the 0.01% atropine group experienced at least one side effect, compared with roughly 72% of the placebo group, and the most common ocular complaints were mild photophobia, allergic conjunctivitis, eye irritation, slight pupil dilation, and blurred vision.¹² The fact that placebo recipients reported similar rates suggests that many of these complaints are just part of using eye drops nightly, not specific drug effects.

When low-dose atropine is combined with orthokeratology lenses, a reasonable concern is whether the drops might harm the cornea or disrupt the tear film over time. A study examining dual therapy found no significant differences in tear production, corneal endothelial cell density, or eye pressure between the combination group and the orthokeratology-only group, though the authors noted that tear film stability and the corneal surface should still be monitored over time.¹³

The Rebound Problem

One of the most frustrating aspects of low-dose atropine treatment is what happens when you stop. In many children, myopia progression accelerates for a period after discontinuation, partially eroding the gains made during treatment. A systematic review and meta-analysis confirmed that this rebound effect is real and follows a pattern: it is more pronounced with higher doses, shorter treatment durations, and younger children.¹⁴

This creates an interesting paradox. Higher concentrations slow myopia more effectively during treatment but tend to produce more rebound when stopped, while 0.01% has less rebound but also less effect in the first place. The practical implication for families is that stopping abruptly isn’t ideal. Many eye doctors now taper the dose gradually or continue treatment until the child’s myopia has stabilized naturally, which typically happens in the late teens. The optimal duration and tapering schedule remain open questions, but the evidence clearly argues against short courses of a year or two followed by abrupt discontinuation, especially in younger children.

Combining Atropine with Other Treatments

Because no single intervention completely halts myopia progression, combining low-dose atropine with optical treatments has become increasingly common. The most studied combination is atropine plus orthokeratology, a technique that uses specially shaped rigid contact lenses worn overnight to temporarily reshape the cornea. A review of all available studies on this combination found that adding low-dose atropine to orthokeratology consistently improved myopia control compared with orthokeratology alone.¹⁵

One randomized trial put numbers on this: after 12 months, children using both orthokeratology and 0.01% atropine had an average axial elongation of 0.10 millimeters, while those using orthokeratology alone had 0.20 millimeters, cutting the growth roughly in half.¹⁶ The logic makes sense: atropine and optical interventions likely slow eye growth through different mechanisms, so stacking them can provide additive benefit.

Spectacle-based approaches are also being combined with atropine. Highly aspherical lenslet (HAL) glasses, a newer type of myopia-control spectacle, have been studied alongside low-concentration atropine. In children with mild myopia, the combination of HAL glasses and atropine slowed progression by about a third of a diopter more than atropine drops alone over the study period.¹⁷ For families who prefer glasses over contact lenses, combining specialized spectacles with nightly drops offers an alternative combination approach.

Formulation and Availability

One under-appreciated wrinkle in the low-dose atropine story is that for years, these drops were not commercially manufactured at the concentrations used in research. Ophthalmologists who wanted to prescribe 0.01% atropine had to send patients to a compounding pharmacy, where the drops were mixed on an individual basis. Compounded drops can vary in quality, and questions about their stability are legitimate. A study testing the shelf life of compounded 0.01% atropine found that solutions stored in standard plastic bottles at room temperature remained stable for six months, both with and without preservative.¹⁸ That’s reassuring, but compounding still introduces variability that a standardized commercial product would avoid.

On the regulatory front, the pharmaceutical company Sydnexis has developed a commercial low-dose atropine product called SYD-101, and the FDA accepted its New Drug Application, with a target decision date in late 2025.¹⁹ If approved, it would be the first FDA-approved low-dose atropine product specifically indicated for myopia management in the United States. Several Asian countries already have commercial formulations available, reflecting the longer history of use in those regions.

Cost-Effectiveness

For a treatment that needs to be used nightly for years, cost matters. A cost-effectiveness analysis compared several myopia interventions head to head and found that 0.05% atropine was cost-effective, with an incremental cost of roughly $220 per diopter of slowing achieved. Outdoor activity was even cheaper, essentially yielding savings rather than costs. Red light therapy, another emerging intervention, came in at about $846 per diopter of slowing.²⁰ In compounded form, a month’s supply of low-dose atropine typically costs families anywhere from $30 to $75 in the United States depending on the pharmacy, though pricing could change significantly once a commercial product hits the market.

Low-Dose Atropine Beyond Myopia

While myopia control dominates the conversation, atropine at low doses has been explored for other conditions. One long-standing use is for excessive drooling (sialorrhea) in patients with Parkinson’s disease. A pilot study found that sublingual atropine drops were a simple and inexpensive treatment for drooling associated with parkinsonism.²¹ The idea is the same: atropine blocks muscarinic receptors, reducing secretion from the salivary glands. In ophthalmology, low-dose atropine is also sometimes used to penalize the stronger eye in children being treated for amblyopia (lazy eye), using its blurring effect therapeutically rather than trying to minimize it. These applications underscore that atropine is a versatile and well-characterized drug, with the “low-dose” myopia formulation representing a creative repurposing of a medication that has been in the pharmacopoeia for more than a century.